Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

(2021) Stephen K. Brannan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

(2021) Yutaro Shimomura et al.   SCHIZOPHRENIA RESEARCH

20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)

(2020) Heidi Taipale et al.   World Psychiatry

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey

(2020) Rajiv Tandon et al.   Annals of General Psychiatry

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

(2020) George A. Keepers et al.   AMERICAN JOURNAL OF PSYCHIATRY

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms

(2019) Robert A. McCutcheon et al.   TRENDS IN NEUROSCIENCES

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

(2019) Maximilian Huhn et al.   LANCET

Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists

(2019) Christoph U. Correll et al.   BMC Psychiatry

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

(2017) Marco Solmi et al.   Therapeutics and Clinical Risk Management

Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release

(2016) Daniel J. Foster et al.   NEURON

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia

(2016) Michael R. Wood et al.   ACS Medicinal Chemistry Letters

Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology

(2015) Leonel E. Rojo et al.   PHARMACOLOGICAL RESEARCH

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

(2015) Christoph U. Correll et al.   World Psychiatry

Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

(2014) Michael Bubser et al.   ACS Chemical Neuroscience

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

(2014) Nellie E Byun et al.   NEUROPSYCHOPHARMACOLOGY

Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

(2013) John M. Kane et al.   World Psychiatry

Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review

(2013) José M Olivares et al.   Annals of General Psychiatry

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

(2012) Eric D. A. Hermes et al.   JOURNAL OF CLINICAL PSYCHIATRY

Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies

(2012) M. Alvarez-Jimenez et al.   SCHIZOPHRENIA RESEARCH

Targeting glutamate synapses in schizophrenia

(2011) Julie R. Field et al.   TRENDS IN MOLECULAR MEDICINE

Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum

(2010) S. Threlfell et al.   JOURNAL OF NEUROSCIENCE

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY